Valuation : GlaxoSmithKline plc

Market Cap 7.23TCr 9.79TCr 8.42TCr 7.93TCr 14TCr 9,31500Cr 14TCr 94TCr 36TCr 4,74500Cr 37TCr 36TCr 15,03300Cr P/E 2026 *
13.8x
P/E 2027 * 11.3x
Enterprise Value 9.3TCr 13TCr 11TCr 10TCr 17TCr 11,98500Cr 17TCr 1,21000Cr 47TCr 6,10600Cr 47TCr 46TCr 19,34400Cr EV / Sales 2026 *
2.74x
EV / Sales 2027 * 2.54x
Free-Float
92.75%
Yield 2026 *
3.86%
Yield 2027 * 4.16%
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-3.09%+49.77%+91.69% 1,00200Cr
-0.76%-2.95%+50.93%+66.34% 64TCr
+0.86%-4.13%+19.24%+68.37% 44TCr
-0.86%-3.06%+29.88%+36.12% 34TCr
+0.80%-14.13%+11.93%+27.69% 26TCr
-0.50%-4.69%-2.84%+10.23% 24TCr
-0.48%-11.65%+39.75%+50.82% 21TCr
-0.16%-4.34%-17.86%-57.82% 20TCr
-0.68%-2.65%+25.82%+91.64% 18TCr
Average +0.17%-5.00%+22.96%+42.79% 39.22TCr
Weighted average by Cap. +0.43%-4.24%+32.12%+57.47%

Financials

2026 *2027 *
Net sales 3.39TCr 4.6TCr 3.96TCr 3.73TCr 6.35TCr 4,37600Cr 6.38TCr 44TCr 17TCr 2,22900Cr 17TCr 17TCr 7,06200Cr 3.55TCr 4.81TCr 4.14TCr 3.9TCr 6.64TCr 4,57500Cr 6.67TCr 46TCr 18TCr 2,33000Cr 18TCr 18TCr 7,38300Cr
Net income 538.05Cr 728.8Cr 627.14Cr 590.51Cr 1.01TCr 69TCr 1.01TCr 7TCr 2.7TCr 35TCr 2.74TCr 2.68TCr 1,11900Cr 637.41Cr 863.39Cr 742.95Cr 699.55Cr 1.19TCr 82TCr 1.2TCr 8.29TCr 3.2TCr 42TCr 3.24TCr 3.17TCr 1,32600Cr
Net Debt 2.07TCr 2.81TCr 2.42TCr 2.27TCr 3.88TCr 2,67100Cr 3.89TCr 27TCr 10TCr 1,36100Cr 11TCr 10TCr 4,31100Cr 1.8TCr 2.44TCr 2.1TCr 1.97TCr 3.37TCr 2,31800Cr 3.38TCr 23TCr 9.04TCr 1,18100Cr 9.15TCr 8.95TCr 3,74100Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!